Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 16, 2011

Lallemand, GM Pharmaceuticals launch Ismigen in Georgia

Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.

Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.

Ismigen, a polyvalent mechanical bacterial lysate, is also used to prevent acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree.

The drug is prepared from a large array of inactivated pathogenic bacteria via mechanical lysis.

Switzerland-based Lallemand Pharma’s key products are comprised of immunostimulant drugs Ismigen, Immubron and Respibron, which target infections of the respiratory tract.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU